Evidence map›Paper›PMID 29669600›Full record

ReviewCancer imaging : the official publication of the International Cancer Imaging Society2018

Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.

Babina Gosangi, Matthew Davids, Bhanusupriya Somarouthu, Francesco Alessandrino, Angela Giardino, Nikhil Ramaiya, Katherine Krajewski

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer imaging : the official publication of the International Cancer Imaging Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Babina GosangiThoracic Radiology, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA. bgosangi@bwh.harvard.edu.ORCID http://orcid.org/0000-0003-4855-4232
Matthew DavidsHarvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.
Bhanusupriya SomarouthuRadiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
Francesco AlessandrinoEmergency Radiology, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA.
Angela GiardinoDepartment of Radiology, Dana Farber Cancer Institute, Boston, MA, 02284, USA.
Nikhil RamaiyaDepartment of Radiology, Dana Farber Cancer Institute, Boston, MA, 02284, USA.
Katherine KrajewskiDepartment of Radiology, Dana Farber Cancer Institute, Boston, MA, 02284, USA.
Dana-Farber Cancer Institute · USBrigham and Women's Hospital · USHarvard University · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The last 5 years have been marked by profound innovation in the targeted treatment of chronic lymphocytic leukemia (CLL) and indolent lymphomas. Using CLL as a case study, we present a timeline and overview of the current treatment landscape for the radiologist, including an overview of clinical and radiological features of CLL, discussion of the targeted agents themselves, and the role of imaging in response and toxicity assessment. The goal is to familiarize the radiologist with multiple Food and Drug Administration (FDA)-approved targeted agents used in this setting and associated adverse events which are commonly observed in this patient population.

Indexed as

Antineoplastic Agents, ImmunologicalHumansLeukemia, Lymphocytic, Chronic, B-CellProtein Kinase InhibitorsRadiographic Image Interpretation, Computer-AssistedTomography, X-Ray ComputedAntineoplastic Agents, ImmunologicalProtein Kinase InhibitorsChronic lymphocytic leukemiaDrug related toxicityIndolent lymphomaTargeted therapy

Identifiers

PMID29669600
PMCPMC5907417
OpenAlexW2799596118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.